Rochester General Health System Installs Masimo Patient SafetyNet(TM) for Advanced Care and Oversight of Patients

IRVINE, CA--(Marketwired - Sep 13, 2013) - Masimo ( NASDAQ : MASI ) today announced that Rochester General Health System and its 528-bed flagship Rochester General Hospital have installed the Masimo Patient SafetyNet™ system, a remote monitoring and clinician notification system shown to dramatically reduce rapid response activations, transfers to intensive care units, and deaths related to opioid-induced respiratory depression.1

Rochester General joins a growing list of prominent health systems around the world using Patient SafetyNet, which combines the performance of Masimo SET® pulse oximetry, the enabler of reliable monitoring in the general ward, with ventilation monitoring and wireless clinician notification. Patient SafetyNet can can help ensure patients' safety by noninvasively and continuously measuring and tracking their underlying physiological conditions and changes that signal declining health status in real-time. When changes occur in the measured values, which may indicate deterioration in the patient's condition, the system automatically sends wireless alerts directly to clinicians -- prompting a potentially lifesaving response to the patient's bedside.

"Masimo provides us with the advanced technologies we need to meet our high standards for patient care," said Claire Aloan, MS, RRT-NPS, FAARC, Director of Respiratory Care Services for the Rochester General Health System. "Patient SafetyNet offers us the ability to respond to patients faster. And Masimo SET® pulse oximetry -- because of its clinical accuracy -- gives us confidence that we're responding to true alarms. This speed and accuracy allows us to improve patient outcomes."

The installation at Rochester General Hospital took place after an extensive evaluation process resulting in the organization's standardization to Masimo SET® Measure-Through Motion and Low Perfusion pulse oximetry. The performance of Masimo SET® pulse oximetry is proven by more than 100 independent and objective studies and thousands of clinical evaluations. Masimo SET® is trusted by clinicians to safely monitor more than 100 million patients each year and is used hospital-wide by eight of the top 10 hospitals on the U.S. News & World Report Best Hospitals Honor Roll (2013-2014). Compared to other pulse oximeters during patient motion and low perfusion, Masimo SET® provides measurements when other pulse oximeters cannot, dramatically reduces false alarms (specificity), and accurately detects true alarms (sensitivity)2,3 that can indicate a deteriorating patient. Most importantly, Masimo SET® pulse oximetry has been shown to improve patient outcomes by helping clinicians reduce retinopathy of prematurity (ROP)4 in neonates, screen newborns for critical congenital heart disease (CCHD),5,6 reduce ventilator weaning time and arterial blood gas measurements in the ICU,7 and save lives and costs while reducing rapid response activations and intensive care unit transfers on the general floor.3

"Rochester General Health System has made patient safety a top priority," said Joe Kiani, Founder and CEO of Masimo. "We are honored to partner with a healthcare facility that is committed to help protect patients, improve outcomes, and reduce costs."

1 Taenzer A, Blike G, McGrath S, Pyke J, Herrick M, Renaud C, Morgan J. "Postoperative Monitoring - The Dartmouth
Experience." Anesthesia Patient Safety Foundation Newsletter Spring-Summer 2012. Available online
2 Shah N, Ragaswamy HB, Govindugari K, Estanol L "Performance of Three New-Generation Pulse Oximeters during Motion and Low Perfusion in Volunteers".J Clin Anesth. 2012 Aug;24(5):385-91.
3 Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T. "Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-and-After Concurrence Study." Anesthesiology, February 2010, Vol. 112, Issue 2. Available online here.
4 Castillo A, et al. Acta Paediatr. 2011 Feb.;100(2):188-92.
5 de-Wahl Granelli A., et al. BMJ. 2009 Jan 8;338.
6 Ewer A, et al. Health Technol Assess. 2012;16(2):1-184.
7 Durbin, et al. Critical Care Medicine. 2002 Aug.;30(8): 1735 to 1740.

About Rochester General Health System
Serving the community of Greater Rochester and beyond, Rochester General Health System (RGHS) has earned national recognition for excellence in a variety of clinical specialties. RGHS is comprised of eight clinically integrated affiliates delivering comprehensive healthcare services with superior quality, safety and patient satisfaction. Rochester General Hospital (RGH), the health system's flagship affiliate, is a 528-bed tertiary care facility that treats more Monroe County patients than any other hospital. RGH, home to the fourth largest cardiac center in New York State, has been recognized nine times as being among the nation's 100 Top Cardiovascular Hospitals. According to the 2013 report from CareChex®, a division of The Delta Group, RGH ranks first in New York for Major Cardiac Surgery (#4 in the nation) and Heart Attack Treatment, #2 in New York for Overall Medical Care and #5 statewide for Overall Surgical Care. For more information, please visit www.rochestergeneral.org

About Masimo
Masimo ( NASDAQ : MASI ) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to help clinicians detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow ® Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures; total hemoglobin (SpHb®), oxygen content (SpOC), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), PVI®, and perfusion index (PI), in addition to measure-through motion SpO2, and pulse rate. In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic Monitoring, the first-ever commercially available noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo SET® and Masimo rainbow® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.

Forward Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions that all neonatal patients at Rochester General Hospital will be cared for using the most technologically and clinically-advanced noninvasive patient monitoring solutions available; risks related to our belief that Masimo Patient SafetyNet can help keep patients safer by noninvasively, continuously measuring and tracking their underlying physiological condition to help hospitals avoid preventable patient deaths and injuries associated with failure to rescue events; risks related to our belief that Masimo SET virtually eliminates false alarms and increases a clinician's ability to detect life-threatening events; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SedLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN is under license from University HealthSystem Consortium.